Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Betahistine for prevention of olanzapine-induced weight gain in psychotic disorder
IRCT20210409050910N2Phase 3Completed
- Sponsor
- Sabzevar University of Medical Sciences
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Schizophrenia Spectrum Disorders (SSD) comparing Olanzapine + betahistine with Olanzapine alone (2 arms). Primary endpoints: Weight and Waist circumference. Started May 2021; status: completed.
02
Drugs
betahistineolanzapine
03
Conditions
Schizophrenia Spectrum Disorders (SSD)
Beyond the preview
Go deeper on IRCT20210409050910N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210409050910N2.